


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): 5-Chloro-2-(1-homopiperazinyl)-7-methylbenzoxazole represented by the following general formula (I) or a salt thereof:



(I)

wherein R¹ represents a halogen atom, R² represents hydrogen atom or a lower alkyl group, and R³ represents hydrogen atom, a lower alkyl group, a lower alkoxy group, a hydroxy lower alkyl group, a halogen atom, or a substituted or unsubstituted amino group, wherein a substituent on the amino group is selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkylcarbonyl group, and an amino protective group.

2-17. (canceled).

18. (new): A medicament which comprises, as an active ingredient, an effective amount of a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

19. (new): A method for the manufacture of the medicament according to claim 20, which comprises mixing a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof, with a pharmaceutical carrier.

20. (new): A method for therapeutic treatment of condition of irritable bowel syndrome or digestive tract functional disorder, or condition of diarrhea, which comprises a step of administering to a mammal including human a therapeutically effective amount of a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

21. (new): A serotonin 5-HT₃ receptor antagonistic agent for therapeutic treatment of condition of irritable bowel syndrome or digestive tract functional disorder, or condition of diarrhea, comprising as an active ingredient, an effective amount of a substance selected from the group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

22. (new): A serotonin 5-HT₃ receptor partial activator for therapeutic treatment of condition of irritable bowel syndrome or digestive tract functional disorder, or condition of diarrhea, comprising as an active ingredient, an effective amount of a substance selected from the

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Appln. No. 09/856,372

group consisting of the compound according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof.

23. (new): An antiemetic agent comprising a serotonin 5-HT₃ receptor antagonistic agent according to claim 23.

24. (new): An antiemetic agent comprising a serotonin 5-HT₃ receptor partial activator according to claim 24.